Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Fortress Biotech, Inc.FBIO · Entity 6822 | SVP, BIOLOGICS OPERATIONS | December 11, 2018 | July 09, 2019 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Fortress Biotech, Inc.
Report date December 11, 2018 · Filed July 09, 2019 · Amendment
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| COMMON STOCK, PAR VALUE $0.001SEC Table I · non-derivative | Direct | 655,170 |
Reported balance
After 2018-12-11 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2018-12-11 · Grant · Acquired 400,000 · Balance 655,170 F1: 400,000 shares of the Issuer's common stock owned by the Reporting Person vested on December 11, 2018, triggering the sale of 97,325 shares of the Issuer's common stock as reported on the Form 4, filed on December 13, 2018 (the "Original Form 4"). The 400,000 shares of the Issuer's common stock were inadvertently omitted from the Original Form 4. |
| Options to purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $9.21 · Expires 2023-06-04 | Direct | 200,000 |
Reported balance
After 2019-04-17 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2019-04-17 · Grant · Acquired 200,000 · Balance 200,000 F2: The options granted were fully vested on June 4, 2016. This grant was reinstated by the Issuer's Board of Directors on April 17, 2019. |
Filing footnotes · ownership attribution and instrument terms
F1: 400,000 shares of the Issuer's common stock owned by the Reporting Person vested on December 11, 2018, triggering the sale of 97,325 shares of the Issuer's common stock as reported on the Form 4, filed on December 13, 2018 (the "Original Form 4"). The 400,000 shares of the Issuer's common stock were inadvertently omitted from the Original Form 4.
F2: The options granted were fully vested on June 4, 2016. This grant was reinstated by the Issuer's Board of Directors on April 17, 2019.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| April 17, 2019 Filed Jul 9, 2019 20:01 UTC Amendment | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantOptions to purchase Common Stock · Derivative | 200,000 | $0.00 Strike: $9.21 | $0.00 |
DisclosureSEC source: 0001144204-19-034107 · tv524928_form4a.xml · derivative · entry 2 Avgerinos George · CIK 0001578699 · SVP, BIOLOGICS OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2023-06-04 F2 · derivative.exercise_date: The options granted were fully vested on June 4, 2016. This grant was reinstated by the Issuer's Board of Directors on April 17, 2019. Read SEC document |
| December 11, 2018 Filed Dec 13, 2018 23:10 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | SaleCOMMON STOCK, PAR VALUE $0.001 | 97,325 | $1.05 | $102,191.25 |
DisclosureSEC source: 0001144204-18-064511 · tv509132_form4.xml · nonDerivative · entry 1 Avgerinos George · CIK 0001578699 · SVP, BIOLOGICS OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 255,170 F1 · shares: The Reporting Person had no discretion with respect to such sale, which was conducted automatically by the Issuer's administrator in order to satisfy the reporting person's tax withholding obligations. F2 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The Reporting Person reported on a single line all such transactions that occurred within a one dollar price range. The range of prices for the sale transactions on December 11, 2018, was $1.03 to $1.10. The Reporting Person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the Issuer, or a shareholder of the Issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 11, 2018 Filed Jul 9, 2019 20:01 UTC Amendment | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCOMMON STOCK, PAR VALUE $0.001 | 400,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-19-034107 · tv524928_form4a.xml · nonDerivative · entry 1 Avgerinos George · CIK 0001578699 · SVP, BIOLOGICS OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 655,170 F1 · shares: 400,000 shares of the Issuer's common stock owned by the Reporting Person vested on December 11, 2018, triggering the sale of 97,325 shares of the Issuer's common stock as reported on the Form 4, filed on December 13, 2018 (the "Original Form 4"). The 400,000 shares of the Issuer's common stock were inadvertently omitted from the Original Form 4. Read SEC document |
| December 14, 2017 Filed Dec 18, 2017 23:46 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | SaleCOMMON STOCK, PAR VALUE $0.001 | 12,000 | $3.55 | $42,600.00 |
DisclosureSEC source: 0001144204-17-064182 · tv481629_form4.xml · nonDerivative · entry 1 Avgerinos George · CIK 0001578699 · SVP, BIOLOGICS OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 352,495 F1 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The range of prices for the sale transactions on December 14, 2017, was $3.53 to $3.68. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 13, 2017 Filed Dec 15, 2017 01:18 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | SaleCOMMON STOCK, PAR VALUE $0.001 | 19,000 | $3.57 | $67,830.00 |
DisclosureSEC source: 0001144204-17-063792 · tv481449_form4.xml · nonDerivative · entry 3 Avgerinos George · CIK 0001578699 · SVP, BIOLOGICS OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 364,495 F2 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The range of prices for the sale transactions on December 12, 2017, was $3.53 to $3.72, and the range of prices for the sale transactions on December 13, 2017, was $3.55 to $3.63. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| December 12, 2017 Filed Dec 15, 2017 01:18 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | SaleCOMMON STOCK, PAR VALUE $0.001 | 25,593 | $3.59 | $91,878.87 |
DisclosureSEC source: 0001144204-17-063792 · tv481449_form4.xml · nonDerivative · entry 2 Avgerinos George · CIK 0001578699 · SVP, BIOLOGICS OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 383,495 F2 · price: Reflects the weighted average sale price of multiple same-way open market sale transactions effected by the Reporting Person on the same day at different prices through a sale order executed by a broker-dealer. The reporting person reported on a single line all such transactions that occurred within a one dollar price range. The range of prices for the sale transactions on December 12, 2017, was $3.53 to $3.72, and the range of prices for the sale transactions on December 13, 2017, was $3.55 to $3.63. The reporting person hereby undertakes to provide upon request by the Securities Exchange Commission staff, the issuer, or a shareholder of the issuer, full information regarding the number of shares sold at each separate price. Read SEC document |
| November 29, 2017 Filed Dec 15, 2017 01:18 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCOMMON STOCK, PAR VALUE $0.001 | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001144204-17-063792 · tv481449_form4.xml · nonDerivative · entry 1 Avgerinos George · CIK 0001578699 · SVP, BIOLOGICS OPERATIONS 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 409,088 F1 · shares: Represents shares of common stock issued to the Reporting Person upon the partial vesting of an award of restricted stock units initially made on July 15, 2015. Read SEC document |
| September 16, 2016 Filed Sep 19, 2016 20:23 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | SaleCommon Stock, par value $0.001 | 33,912 | $2.55 | $86,475.60 |
DisclosureSEC source: 0001638599-16-001415 · doc4_4237.xml · nonDerivative · entry 2 Avgerinos George · CIK 0001578699 · SVP, Biologics Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,088 F2 · price: This transaction was executed in multiple trades ranging from $2.53 to $2.62. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| September 15, 2016 Filed Sep 19, 2016 20:23 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | SaleCommon Stock, par value $0.001 | 15,000 | $2.54 | $38,100.00 |
DisclosureSEC source: 0001638599-16-001415 · doc4_4237.xml · nonDerivative · entry 1 Avgerinos George · CIK 0001578699 · SVP, Biologics Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 293,000 F1 · price: This transaction was executed in multiple trades ranging from $2.49 to $2.58. The price reported in Column 4 is a weighted average price. The reporting person hereby undertakes to provide upon request to the SEC staff, the Issuer or a security holder of the Issuer full information regarding the number of shares and prices at which the transactions were effected. Read SEC document |
| September 14, 2016 Filed Sep 16, 2016 20:08 UTC | Fortress Biotech, Inc. FBIO · Entity 6822 | GrantCommon Stock, par value $0.001 | 150,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001638599-16-001407 · doc4_4232.xml · nonDerivative · entry 1 Avgerinos George · CIK 0001578699 · SVP, Biologics Operations 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 308,000 F1 · shares: Represents shares of common stock issued to the Reporting Person upon the partial vesting of an award of restricted stock units initially made on July 15, 2015. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.